KR20130121685A - 안과용 조성물 - Google Patents

안과용 조성물 Download PDF

Info

Publication number
KR20130121685A
KR20130121685A KR1020127031915A KR20127031915A KR20130121685A KR 20130121685 A KR20130121685 A KR 20130121685A KR 1020127031915 A KR1020127031915 A KR 1020127031915A KR 20127031915 A KR20127031915 A KR 20127031915A KR 20130121685 A KR20130121685 A KR 20130121685A
Authority
KR
South Korea
Prior art keywords
timolol
ophthalmic composition
dorzolamide
polysorbate
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127031915A
Other languages
English (en)
Korean (ko)
Inventor
준 이노우에
타판 샤흐
Original Assignee
센주 유에스에이, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센주 유에스에이, 인코포레이티드 filed Critical 센주 유에스에이, 인코포레이티드
Publication of KR20130121685A publication Critical patent/KR20130121685A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020127031915A 2010-05-05 2011-05-04 안과용 조성물 Withdrawn KR20130121685A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/774,419 US8211450B2 (en) 2010-05-05 2010-05-05 Ophthalmic composition
US12/774,419 2010-05-05
PCT/US2011/035147 WO2011140194A1 (en) 2010-05-05 2011-05-04 Ophthalmic composition

Publications (1)

Publication Number Publication Date
KR20130121685A true KR20130121685A (ko) 2013-11-06

Family

ID=44902332

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127031915A Withdrawn KR20130121685A (ko) 2010-05-05 2011-05-04 안과용 조성물

Country Status (8)

Country Link
US (2) US8211450B2 (https=)
EP (1) EP2566487A4 (https=)
JP (1) JP2013528589A (https=)
KR (1) KR20130121685A (https=)
CN (1) CN103096901A (https=)
CA (1) CA2797123A1 (https=)
MX (1) MX2012012846A (https=)
WO (1) WO2011140194A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170014533A (ko) 2015-07-30 2017-02-08 포항공과대학교 산학협력단 생체적합성 각막세포 전구체 분화방법 및 각막세포 전구체 조성물

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY158722A (en) * 2010-07-29 2016-11-15 Santen Pharmaceutical Co Ltd "drug support body, and method for producing same"
WO2013114397A2 (en) * 2012-01-16 2013-08-08 Biocon Limited Pharmaceutically acceptable salt of brinzolamide and composition thereof
US9820991B2 (en) * 2013-11-08 2017-11-21 Sentiss Pharma Private Limited Pharmaceutical composition comprising brinzolamide
CN103740831B (zh) * 2014-01-13 2015-01-28 宁波海尔施基因科技有限公司 一种指导β-受体阻断药用药的引物组合物、多重基因检测试剂盒及其使用方法
JP6487452B2 (ja) * 2014-01-24 2019-03-20 センティス ファーマ プライベート リミテッド ブリンゾラミドを含む医薬組成物
ES2805459T3 (es) 2014-05-16 2021-02-12 Occidental Chem Co Método para fabricar 1,1,3,3-tetracloropropeno
JP6373995B2 (ja) * 2014-07-11 2018-08-15 富士フイルム株式会社 眼科用水性組成物
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
JP6050454B1 (ja) * 2015-09-28 2016-12-21 参天製薬株式会社 水性医薬組成物
TW201733577A (zh) * 2016-03-14 2017-10-01 Santen Pharmaceutical Co Ltd 含有多佐胺、噻嗎洛爾和界面活性劑之醫藥組成物
WO2019118928A1 (en) 2017-12-15 2019-06-20 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
WO2021018750A1 (en) 2019-07-26 2021-02-04 Proqr Therapeutics Ii B.V. Ophthalmic compositions comprising viscosifying polymers and nucleic acids
KR20240134913A (ko) 2022-01-21 2024-09-10 센주 유에스에이, 인코포레이티드 수성 액제
CN118978426B (zh) * 2024-10-22 2025-05-16 浙江大学 一种甘油的酸化处理方法、酸化甘油及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136014A (en) * 1990-06-22 1992-08-04 E. I. Du Pont De Nemours And Company Hyperbranched polyesters
CZ285129B6 (cs) * 1991-04-17 1999-05-12 Merck & Co., Inc. Oftalmické přípravky, obsahující kombinace inhibitoru karboanhydrasy a beta-adrenergního antagonisty
US6316443B1 (en) * 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
FR2772771B1 (fr) * 1997-12-19 2000-01-28 Oreal Utilisation de polymeres hyperbranches et de dendrimeres comportant un groupement particulier, en tant qu'agent filmogene, les compositions filmogenes les comprenant et leur utilisation notamment en cosmetique ou en pharmacie
WO2000063409A1 (en) 1999-04-21 2000-10-26 Massachusetts Institute Of Technology Endosomolytic agents and cell delivery systems
US7030097B1 (en) 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
SK282717B6 (sk) 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Spôsob prípravy ultravysokomolekulových hyalurónanov
US7097856B2 (en) 2000-09-29 2006-08-29 The Regents Of The University Of California Dendrimeric support or carrier macromolecule
JP2004523624A (ja) 2001-02-26 2004-08-05 デューク ユニバーシティ 新規なデンドリティックポリマー、およびその生物医学的使用
AU2002304314B2 (en) 2001-03-08 2007-09-06 Nyomox Pharmaceutical Corporation Using neural thread proteins to treat tumors and other hyperproliferative disorders
FR2830450B1 (fr) 2001-10-09 2004-02-06 Univ Pasteur Utilisation de dendrimeres dans une composition ophtalmique
AR038269A1 (es) 2002-01-09 2005-01-12 Novartis Ag Articulos polimericos que tienen un recubrimiento lubrico, y metodo para fabricarlos
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
KR20050111586A (ko) * 2003-02-13 2005-11-25 내셔널 센터 포 사이언티픽 리서치 데모크리토스 드러그 및 유전자 전달 시스템으로서의 다기능의 덴드리머및 다중결합된 폴리머
JP2005008614A (ja) 2003-03-28 2005-01-13 Nano Career Kk 高分子ミセルを用いた眼科用ドラッグデリバリーシステム
US7109247B2 (en) 2003-05-30 2006-09-19 3M Innovative Properties Company Stabilized particle dispersions containing nanoparticles
US7189456B2 (en) 2004-03-04 2007-03-13 Transitions Optical, Inc. Photochromic optical article
WO2006031358A2 (en) 2004-08-13 2006-03-23 Hyperbranch Medical Technology, Inc. Dendritic polymers, crosslinked gels, and their uses as ophthalmic sealants and lenses
US20060057215A1 (en) * 2004-09-15 2006-03-16 Raiche Adrian T Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
US7837986B2 (en) 2004-12-01 2010-11-23 E. I. Du Pont De Nemours And Company Protein-based polymer tissue adhesives for medical use
US20090041813A1 (en) * 2005-02-21 2009-02-12 Basf Aktiengesellschaft Active substance composition comprising at least one nitrogen atom-containing, hyperbranched polymer
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US8679536B2 (en) 2005-08-24 2014-03-25 Actamax Surgical Materials, Llc Aldol-crosslinked polymeric hydrogel adhesives
US7666331B2 (en) 2005-08-31 2010-02-23 Transitions Optical, Inc. Photochromic article
CN104524596B (zh) 2006-01-20 2018-10-09 星药股份有限公司 经修饰的大分子
US20090012033A1 (en) 2006-03-03 2009-01-08 Demattei Cordell R Delivery of Biologically Active Materials Using Core-Shell Tecto(Dendritic Polymers)
US20080031916A1 (en) * 2006-04-24 2008-02-07 Heather Sheardown Dendrimer cross-linked collagen
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
US20090324742A1 (en) 2006-09-08 2009-12-31 Sonke Svenson Peham dendrimers as excipients
TWI409081B (zh) * 2006-11-09 2013-09-21 Alcon Res Ltd 用於藥物輸送之水不溶性聚合物基質
US7906214B2 (en) 2007-01-26 2011-03-15 Transitions Optical, Inc. Optical elements comprising compatiblizing coatings and methods of making the same
JP5484339B2 (ja) * 2007-10-05 2014-05-07 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
WO2009064963A2 (en) 2007-11-14 2009-05-22 E. I. Du Pont De Nemours And Company Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use
US20100008993A1 (en) 2008-07-14 2010-01-14 Proksch Joel W Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs
WO2010017184A2 (en) * 2008-08-08 2010-02-11 Virginia Commonwealth University Dendrimer hydrogels

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170014533A (ko) 2015-07-30 2017-02-08 포항공과대학교 산학협력단 생체적합성 각막세포 전구체 분화방법 및 각막세포 전구체 조성물

Also Published As

Publication number Publication date
EP2566487A4 (en) 2014-06-18
EP2566487A1 (en) 2013-03-13
CN103096901A (zh) 2013-05-08
CA2797123A1 (en) 2011-11-10
US8211450B2 (en) 2012-07-03
JP2013528589A (ja) 2013-07-11
MX2012012846A (es) 2013-05-22
US20110275617A1 (en) 2011-11-10
US20130053374A1 (en) 2013-02-28
WO2011140194A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
KR20130121685A (ko) 안과용 조성물
KR102525438B1 (ko) 안과용 활성 약학 성분 전달을 위한 고형 사이클로덱스트린 복합체의 제조
EP2763654B1 (en) Ophthtalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid
JP5745666B2 (ja) 面状両親媒性ポリマー及びオリゴマーの眼科用及び耳科用組成物とその使用
EP3179982B1 (en) Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
JP2021165299A (ja) 薬学的組成物、および１，２，４−オキサジアゾール安息香酸の塩
JP7236484B2 (ja) 薬剤搭載ナノ樹脂粒子
Ricci et al. Chitosan/sulfobutylether-β-cyclodextrin based nanoparticles coated with thiolated hyaluronic acid for indomethacin ophthalmic delivery
EP3993807B1 (en) Method for stabilizing the ph of an aqueous composition comprising a drug
TW201110961A (en) Ophthalmic composition
US20110178145A1 (en) Alpha-2 adrenergic agonist having long duration ofintraocular pressure-lowering effect
US12336971B2 (en) Ophthalmic pharmaceutical compositions and uses thereof
WO2006049250A1 (ja) 眼内移行性促進水性点眼剤
JP7459298B2 (ja) 細胞透過性核酸複合体を有効成分として含有する黄斑変性の予防又は治療用組成物
Lu Recent advances in developing ophthalmic formulations: a patent review
KR101923519B1 (ko) 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
CN102198087B (zh) 一种不含防腐剂的眼用原位胶凝剂及其制备方法
US20230218611A1 (en) Ophthalmic compositions comprising a combination of brinzolamide and brimonidine
EP2827838B1 (en) Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof
WO2021113637A1 (en) Ophthalmic formulations for the treatment of presbyopia
Lorenzo Veiga Cyclodextrin nanostructures and ocular drug delivery
CN104721130A (zh) 一种布佐林胺包合物眼用制剂及其制备方法
More et al. DevelopmentandEvaluationofTimololMaleateloadedBilosomes.
JP2025136503A (ja) 眼表面薬物滞留化剤および該剤を含有する点眼剤
US20130210876A1 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121205

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid